Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL™ Cerebral Protection System PR Newswire Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH,...
Summary Glenview Capital Management’s 13F portfolio value decreased from $4.94B to $4B this quarter. The number of positions decreased from 60 to 55. They increased Cigna, Aptiv plc, and Change Healthcare while dropping Bausch Health, Meritor, and AmerisourceBergen. The...
--News Direct-- On Feb. 24, Tomasz was at home, about to enjoy a cold beverage while watching the evening news, when he first found out that Russia had invaded Ukraine. For Tomasz, floating team supervisor for the Boston Scientific EMEA team based in Poland, it was a call to action. Wit...
Summary Shares are down 25% year to date. Covid limited Inari's ability to develop the DVT market, so a post-pandemic constructive hospital environment provides them a nice tailwind going forward. Product offerings including ClotTriever are providing superior outcomes for pati...
Summary Nevro Corp remains an attractive play in chronic non-specific lower back pain and diabetic peripheral neuropathy. It came in with a strong set of quarterly numbers last period demonstrating robust top-line growth. Shares are trading in line with our estimate of fair va...
Boston Scientific ( NYSE: BSX ) said it received U.S. Food and Drug Administration (FDA) approval the expanded labeling for for the current-generation Watchman FLX Left Atrial Appendage Closure (LAAC) Device. The new labeling instruction allows, to include a 45-day dua...
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option PR Newswire WATCHMAN FLX now the only LAAC technology in the United States that allows for either D...
Summary This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total retu...
News, Short Squeeze, Breakout and More Instantly...
Boston Scientific Corporation Company Name:
BSX Stock Symbol:
NYSE Market:
Boston Scientific Corporation Website:
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Boston Scientific Announces Results for Second Quarter 2024 PR Newswire MARLBOROUGH, Mass. , July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent ...
Shares of Boston Scientific Corporation (NYSE: BSX) traded at a new 52-week high today and are currently trading at $78.31. So far today, approximately 1.5M shares have been exchanged, as compared to an average 30-day volume of 5.37M shares. Boston Scientific Corporation develops, manufacture...